Antigen-based vs. systemic immunomodulation in type 1 diabetes

References

• Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027 - 33; http://dx.doi.org/10.1016/S0140-6736(09)60568-7; PMID: 19481249
   PubMed Web of Science ®Google Scholar
• Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010; 10:501 - 13; http://dx.doi.org/10.1038/nri2787; PMID: 20577267
   PubMed Web of Science ®Google Scholar
• The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37:1574 - 82; http://dx.doi.org/10.2337/diabetes.37.11.1574; PMID: 2903105
   PubMed Web of Science ®Google Scholar
• Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2:119 - 24; http://dx.doi.org/10.1016/S0140-6736(86)91943-4; PMID: 2873396
   PubMed Web of Science ®Google Scholar
• Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318:663 - 70; http://dx.doi.org/10.1056/NEJM198803173181103; PMID: 3125434
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763 - 9; http://dx.doi.org/10.2337/diabetes.54.6.1763; PMID: 15919798
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598 - 608; http://dx.doi.org/10.1056/NEJMoa043980; PMID: 15972866
   PubMed Web of Science ®Google Scholar
• Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr., et al, Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487 - 97; http://dx.doi.org/10.1016/S0140-6736(11)60931-8; PMID: 21719095
   PubMed Web of Science ®Google Scholar
• Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale. Diabetes Metab Res Rev 2009; 25:321 - 4; http://dx.doi.org/10.1002/dmrr.960; PMID: 19405081
   PubMed Web of Science ®Google Scholar
• Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al, Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412 - 9; http://dx.doi.org/10.1016/S0140-6736(11)60886-6; PMID: 21719096
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al, Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143 - 52; http://dx.doi.org/10.1056/NEJMoa0904452; PMID: 19940299
   PubMed Web of Science ®Google Scholar
• Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33:1443 - 8; http://dx.doi.org/10.2337/dc09-2297; PMID: 20357369
   PubMed Web of Science ®Google Scholar
• Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, et al, IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 2006; 23:920 - 3; http://dx.doi.org/10.1111/j.1464-5491.2006.01921.x; PMID: 16911633
   PubMed Web of Science ®Google Scholar
• Li X, Liao L, Yan X, Huang G, Lin J, Lei M, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009; 25:411 - 6; http://dx.doi.org/10.1002/dmrr.977; PMID: 19488999
   PubMed Web of Science ®Google Scholar
• Bock G, Prietl B, Mader JK, Höller E, Wolf M, Pilz S, et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab Res Rev 2011; 27:942 - 5; http://dx.doi.org/10.1002/dmrr.1276; PMID: 22069289
   PubMed Web of Science ®Google Scholar
• Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant 2012; 2012:230386; http://dx.doi.org/10.1155/2012/230386; PMID: 22263104
   PubMedGoogle Scholar
• Laupacis A, Stiller CR, Gardell C, Keown P, Dupre J, Wallace AC, et al. Cyclosporin prevents diabetes in BB Wistar rats. Lancet 1983; 1:10 - 2; http://dx.doi.org/10.1016/S0140-6736(83)91558-1; PMID: 6129365
   PubMed Web of Science ®Google Scholar
• Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Laupacis A, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223:1362 - 7; http://dx.doi.org/10.1126/science.6367043; PMID: 6367043
   PubMed Web of Science ®Google Scholar
• Dupré J, Stiller CR, Gent M, Donner A, von Graffenreid B, Murphy G, et al. Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months. Transplant Proc 1988; 20:Suppl 4 184 - 92; PMID: 3289204
   PubMedGoogle Scholar
• Martin S, Schernthaner G, Nerup J, Gries FA, Koivisto VA, Dupré J, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34:429 - 34; http://dx.doi.org/10.1007/BF00403182; PMID: 1884902
   PubMed Web of Science ®Google Scholar
• Bougnères PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39:1264 - 72; http://dx.doi.org/10.2337/diabetes.39.10.1264; PMID: 2210078
   PubMed Web of Science ®Google Scholar
• Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999; 22:478 - 83; http://dx.doi.org/10.2337/diacare.22.3.478; PMID: 10097932
   PubMed Web of Science ®Google Scholar
• Assan R, Blanchet F, Feutren G, Timsit J, Larger E, Boitard C, et al. Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab Res Rev 2002; 18:464 - 72; http://dx.doi.org/10.1002/dmrr.325; PMID: 12469360
   PubMed Web of Science ®Google Scholar
• Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32:535 - 9; http://dx.doi.org/10.1097/00007890-198112000-00018; PMID: 7041358
   PubMed Web of Science ®Google Scholar
• Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155:1544 - 55; PMID: 7636216
   PubMed Web of Science ®Google Scholar
• Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20:509 - 15; http://dx.doi.org/10.1002/eji.1830200308; PMID: 2138557
   PubMed Web of Science ®Google Scholar
• Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25:1492 - 6; http://dx.doi.org/10.1002/eji.1830250603; PMID: 7614975
   PubMed Web of Science ®Google Scholar
• Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000; 200:16 - 26; http://dx.doi.org/10.1006/cimm.2000.1617; PMID: 10716879
   PubMed Web of Science ®Google Scholar
• Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403 - 11; http://dx.doi.org/10.1002/eji.1830230216; PMID: 8436176
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947 - 54; PMID: 9058834
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994; 91:123 - 7; http://dx.doi.org/10.1073/pnas.91.1.123; PMID: 8278351
   PubMed Web of Science ®Google Scholar
• Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011; 187:2015 - 22; http://dx.doi.org/10.4049/jimmunol.1100713; PMID: 21742976
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622 - 32; http://dx.doi.org/10.1038/nri2134; PMID: 17641665
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12:979 - 82; http://dx.doi.org/10.1002/eji.1830121116; PMID: 6759145
   PubMed Web of Science ®Google Scholar
• Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med 2010; 207:1879 - 89; http://dx.doi.org/10.1084/jem.20100205; PMID: 20679403
   PubMed Web of Science ®Google Scholar
• Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202 - 8; http://dx.doi.org/10.1038/nm924; PMID: 12937416
   PubMed Web of Science ®Google Scholar
• You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007; 104:6335 - 40; http://dx.doi.org/10.1073/pnas.0701171104; PMID: 17389382
   PubMed Web of Science ®Google Scholar
• Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 2012; 4:18ra12; http://dx.doi.org/10.1126/scitranslmed.3003401; PMID: 22277969
   PubMedGoogle Scholar
• Kuhn C, You S, Valette F, Hale G, van Endert P, Bach JF, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med 2011; 3:68ra10; http://dx.doi.org/10.1126/scitranslmed.3001830; PMID: 21289272
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692 - 8; http://dx.doi.org/10.1056/NEJMoa012864; PMID: 12037148
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, et al, Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132:166 - 73; http://dx.doi.org/10.1016/j.clim.2009.04.007; PMID: 19443276
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614 - 23; http://dx.doi.org/10.1007/s00125-009-1644-9; PMID: 20225393
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010; 115:1145 - 55; http://dx.doi.org/10.1182/blood-2009-02-204875; PMID: 20007541
   PubMed Web of Science ®Google Scholar
• Alkemade GM, Hilbrands R, Vandemeulebroucke E, Pipeleers D, Waldmann H, Mathieu C, et al. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes Metab Res Rev 2011; 27:925 - 7; http://dx.doi.org/10.1002/dmrr.1273; PMID: 22069286
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29:63 - 7; http://dx.doi.org/10.1007/BF02427283; PMID: 3514344
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Mandrup-Poulsen T. A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44:2115 - 33; http://dx.doi.org/10.1007/s001250100021; PMID: 11793013
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32:1663 - 8; http://dx.doi.org/10.2337/dc09-0533; PMID: 19542207
   PubMed Web of Science ®Google Scholar
• Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:2838 - 46; http://dx.doi.org/10.1002/art.10578; PMID: 12428223
   PubMed Web of Science ®Google Scholar
• Moran A, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, et al, for the Type 1 Diabetes TrialNet Canakinumab Study Group, for the AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013; In press http://dx.doi.org/10.1016/S0140-6736(13)60023-9; PMID: 23562090
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12 - 26; http://dx.doi.org/10.1111/j.1600-065X.2009.00770.x; PMID: 19426212
   PubMed Web of Science ®Google Scholar
• Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229:307 - 21; http://dx.doi.org/10.1111/j.1600-065X.2009.00780.x; PMID: 19426230
   PubMed Web of Science ®Google Scholar
• Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243 - 52; http://dx.doi.org/10.1172/JCI5857; PMID: 10225967
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907 - 15; http://dx.doi.org/10.1056/NEJMoa035075; PMID: 14614165
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181:1145 - 55; http://dx.doi.org/10.1084/jem.181.3.1145; PMID: 7532678
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443 - 53; http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x; PMID: 15707398
   PubMed Web of Science ®Google Scholar
• Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036 - 40; http://dx.doi.org/10.1056/NEJMoa010465; PMID: 11586956
   PubMed Web of Science ®Google Scholar
• Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857 - 67; http://dx.doi.org/10.1172/JCI32405; PMID: 18060033
   PubMed Web of Science ®Google Scholar
• Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005; 16:261 - 6; http://dx.doi.org/10.1016/j.tem.2005.06.004; PMID: 15996876
   PubMed Web of Science ®Google Scholar
• Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37:552 - 8; http://dx.doi.org/10.1007/BF00403372; PMID: 7926338
   PubMed Web of Science ®Google Scholar
• Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51:1367 - 74; http://dx.doi.org/10.2337/diabetes.51.5.1367; PMID: 11978632
   PubMed Web of Science ®Google Scholar
• Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003; 417:77 - 80; http://dx.doi.org/10.1016/S0003-9861(03)00338-2; PMID: 12921782
   PubMed Web of Science ®Google Scholar
• Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358:1500 - 3; http://dx.doi.org/10.1016/S0140-6736(01)06580-1; PMID: 11705562
   PubMed Web of Science ®Google Scholar
• Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999; 42:51 - 4; http://dx.doi.org/10.1007/s001250051112; PMID: 10027578
   PubMed Web of Science ®Google Scholar
• Kang EM, Zickler PP, Burns S, Langemeijer SM, Brenner S, Phang OA, et al. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol 2005; 33:699 - 705; http://dx.doi.org/10.1016/j.exphem.2005.03.008; PMID: 15911094
   PubMed Web of Science ®Google Scholar
• Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297:1568 - 76; http://dx.doi.org/10.1001/jama.297.14.1568; PMID: 17426276
   PubMed Web of Science ®Google Scholar
• Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:1573 - 9; http://dx.doi.org/10.1001/jama.2009.470; PMID: 19366777
   PubMed Web of Science ®Google Scholar
• Karges WJ, Ilonen J, Robinson BH, Dosch HM. Self and non-self antigen in diabetic autoimmunity: molecules and mechanisms. Mol Aspects Med 1995; 16:79 - 213; http://dx.doi.org/10.1016/0098-2997(95)00001-W; PMID: 7658921
   PubMed Web of Science ®Google Scholar
• Kawasaki E, Eisenbarth GS. High-throughput radioassays for autoantibodies to recombinant autoantigens. Front Biosci 2000; 5:E181 - 90; http://dx.doi.org/10.2741/kawasaki; PMID: 11056082
   PubMed Web of Science ®Google Scholar
• Long AE, Gooneratne AT, Rokni S, Williams AJ, Bingley PJ. The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort. J Clin Endocrinol Metab 2012; 97:632 - 7; PMID: 22162482
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464:1293 - 300; http://dx.doi.org/10.1038/nature08933; PMID: 20432533
   PubMed Web of Science ®Google Scholar
• Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008; 7:550 - 7; http://dx.doi.org/10.1016/j.autrev.2008.04.008; PMID: 18625444
   PubMed Web of Science ®Google Scholar
• Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, et al, Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:2269 - 74; http://dx.doi.org/10.2337/dc09-0934; PMID: 19741189
   PubMed Web of Science ®Google Scholar
• Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148:1 - 16; http://dx.doi.org/10.1111/j.1365-2249.2006.03244.x; PMID: 17349009
   PubMed Web of Science ®Google Scholar
• Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11:225 - 31; http://dx.doi.org/10.1038/ni.1844; PMID: 20139986
   PubMed Web of Science ®Google Scholar
• Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 2003; 100:8384 - 8; http://dx.doi.org/10.1073/pnas.0932778100; PMID: 12815107
   PubMed Web of Science ®Google Scholar
• Li SW, Koya V, Li Y, Donelan W, Lin P, Reeves WH, et al. Pancreatic duodenal homeobox 1 protein is a novel beta-cell-specific autoantigen for type I diabetes. Lab Invest 2010; 90:31 - 9; http://dx.doi.org/10.1038/labinvest.2009.116; PMID: 19901909
   PubMed Web of Science ®Google Scholar
• Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes 2011; 60:2325 - 30; http://dx.doi.org/10.2337/db11-0288; PMID: 21734016
   PubMed Web of Science ®Google Scholar
• Nakayama M. Insulin as a key autoantigen in the development of type 1 diabetes. Diabetes Metab Res Rev 2011; 27:773 - 7; http://dx.doi.org/10.1002/dmrr.1250; PMID: 22069258
   PubMed Web of Science ®Google Scholar
• Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003; 100:10376 - 81; http://dx.doi.org/10.1073/pnas.1834450100; PMID: 12925730
   PubMed Web of Science ®Google Scholar
• Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996; 93:956 - 60; http://dx.doi.org/10.1073/pnas.93.2.956; PMID: 8570667
   PubMed Web of Science ®Google Scholar
• Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001; 107:173 - 80; http://dx.doi.org/10.1172/JCI8525; PMID: 11160133
   PubMed Web of Science ®Google Scholar
• Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 2000; 97:1701 - 6; http://dx.doi.org/10.1073/pnas.040556697; PMID: 10677521
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med 2003; 197:1635 - 44; http://dx.doi.org/10.1084/jem.20030215; PMID: 12796471
   PubMed Web of Science ®Google Scholar
• Kash SF, Condie BG, Baekkeskov S. Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Horm Metab Res 1999; 31:340 - 4; http://dx.doi.org/10.1055/s-2007-978750; PMID: 10422732
   PubMed Web of Science ®Google Scholar
• Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetologia 2004; 47:149 - 50; http://dx.doi.org/10.1007/s00125-003-1252-z; PMID: 14614561
   PubMed Web of Science ®Google Scholar
• Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999; 284:1183 - 7; http://dx.doi.org/10.1126/science.284.5417.1183; PMID: 10325232
   PubMed Web of Science ®Google Scholar
• Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366:72 - 5; http://dx.doi.org/10.1038/366072a0; PMID: 8232539
   PubMed Web of Science ®Google Scholar
• Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69 - 72; http://dx.doi.org/10.1038/366069a0; PMID: 7694152
   PubMed Web of Science ®Google Scholar
• Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9:379 - 83; http://dx.doi.org/10.1006/jaut.1996.0051; PMID: 8816974
   PubMed Web of Science ®Google Scholar
• Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008; 4:334 - 43; PMID: 18446141
   PubMedGoogle Scholar
• Knip M, Kukko M, Kulmala P, Veijola R, Simell O, Akerblom HK, et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet 2002; 115:48 - 54; http://dx.doi.org/10.1002/ajmg.10343; PMID: 12116176
   PubMed Web of Science ®Google Scholar
• You S, Chatenoud L. Proinsulin: a unique autoantigen triggering autoimmune diabetes. J Clin Invest 2006; 116:3108 - 10; http://dx.doi.org/10.1172/JCI30760; PMID: 17143326
   PubMed Web of Science ®Google Scholar
• Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006; 13:143 - 57; http://dx.doi.org/10.1080/17402520600876804; PMID: 17162357
   PubMed Web of Science ®Google Scholar
• al-Sabbagh A, Miller A, Santos LM, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994; 24:2104 - 9; http://dx.doi.org/10.1002/eji.1830240926; PMID: 7522160
   PubMed Web of Science ®Google Scholar
• Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev 2011; 241:241 - 59; http://dx.doi.org/10.1111/j.1600-065X.2011.01017.x; PMID: 21488901
   PubMed Web of Science ®Google Scholar
• Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997; 186:2039 - 43; http://dx.doi.org/10.1084/jem.186.12.2039; PMID: 9396773
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Trial--Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685 - 91; http://dx.doi.org/10.1056/NEJMoa012350; PMID: 12037147
   PubMed Web of Science ®Google Scholar
• Vandemeulebroucke E, Gorus FK, Decochez K, Weets I, Keymeulen B, De Block C, et al, Belgian Diabetes Registry. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab 2009; 35:319 - 27; http://dx.doi.org/10.1016/j.diabet.2009.02.005; PMID: 19647467
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care 2005; 28:1068 - 76; http://dx.doi.org/10.2337/diacare.28.5.1068; PMID: 15855569
   PubMed Web of Science ®Google Scholar
• Carel JC, Landais P, Bougnères P. Therapy to prevent type 1 diabetes mellitus. N Engl J Med 2002; 347:1115 - 6; http://dx.doi.org/10.1056/NEJM200210033471415; PMID: 12362017
   PubMed Web of Science ®Google Scholar
• Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet 2000; 356:545 - 9; http://dx.doi.org/10.1016/S0140-6736(00)02579-4; PMID: 10950231
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A, et al, IMDIAB Group. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). Diabetologia 2000; 43:1000 - 4; http://dx.doi.org/10.1007/s001250051482; PMID: 10990077
   PubMed Web of Science ®Google Scholar
• Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann N Y Acad Sci 2004; 1029:260 - 77; http://dx.doi.org/10.1196/annals.1309.057; PMID: 15681764
   PubMed Web of Science ®Google Scholar
• Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:1746 - 55; http://dx.doi.org/10.1016/S0140-6736(08)61309-4; PMID: 18814906
   PubMed Web of Science ®Google Scholar
• Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011; 60:1237 - 45; http://dx.doi.org/10.2337/db10-1360; PMID: 21307076
   PubMed Web of Science ®Google Scholar
• Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19:238 - 46; http://dx.doi.org/10.1016/j.jdiacomp.2004.12.003; PMID: 15993359
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909 - 20; http://dx.doi.org/10.1056/NEJMoa0804328; PMID: 18843118
   PubMed Web of Science ®Google Scholar
• Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al, Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378:319 - 27; http://dx.doi.org/10.1016/S0140-6736(11)60895-7; PMID: 21714999
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433 - 42; http://dx.doi.org/10.1056/NEJMoa1107096; PMID: 22296077
   PubMed Web of Science ®Google Scholar
• Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 2001; 16:21 - 8; http://dx.doi.org/10.1006/jaut.2000.0471; PMID: 11221993
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991; 88:10252 - 6; http://dx.doi.org/10.1073/pnas.88.22.10252; PMID: 1946445
   PubMed Web of Science ®Google Scholar
• Prasad S, Kohm AP, McMahon JS, Luo X, Miller SD. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun 2012; 39:347 - 53; http://dx.doi.org/10.1016/j.jaut.2012.04.005; PMID: 22647732
   PubMed Web of Science ®Google Scholar
• Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167 - 74; http://dx.doi.org/10.1084/jem.184.6.2167; PMID: 8976172
   PubMed Web of Science ®Google Scholar
• Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 2006; 176:4608 - 15; PMID: 16585551
   PubMed Web of Science ®Google Scholar
• Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435:220 - 3; http://dx.doi.org/10.1038/nature03523; PMID: 15889095
   PubMed Web of Science ®Google Scholar
• Nakayama M, Babaya N, Miao D, Gianani R, Liu E, Elliott JF, et al. Long-term prevention of diabetes and marked suppression of insulin autoantibodies and insulitis in mice lacking native insulin B9-23 sequence. Ann N Y Acad Sci 2006; 1079:122 - 9; http://dx.doi.org/10.1196/annals.1375.018; PMID: 17130542
   PubMed Web of Science ®Google Scholar
• Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP, DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011; 34:1585 - 90; http://dx.doi.org/10.2337/dc11-0523; PMID: 21610124
   PubMed Web of Science ®Google Scholar
• Ryhänen SJ, Härkönen T, Siljander H, Näntö-Salonen K, Simell T, Hyöty H, et al. Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetes Care 2011; 34:1383 - 8; http://dx.doi.org/10.2337/dc10-1449; PMID: 21515841
   PubMed Web of Science ®Google Scholar
• Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408 - 15; http://dx.doi.org/10.1016/j.jaut.2009.10.005; PMID: 19931408
   PubMed Web of Science ®Google Scholar
• Jun HS, Khil LY, Yoon JW. Role of glutamic acid decarboxylase in the pathogenesis of type 1 diabetes. Cell Mol Life Sci 2002; 59:1892 - 901; http://dx.doi.org/10.1007/PL00012512; PMID: 12530520
   PubMed Web of Science ®Google Scholar
• Björk E, Kämpe O, Karlsson FA, Pipeleers DG, Andersson A, Hellerström C, et al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992; 75:1574 - 6; http://dx.doi.org/10.1210/jc.75.6.1574; PMID: 1464667
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev 2009; 25:307 - 15; http://dx.doi.org/10.1002/dmrr.941; PMID: 19267332
   PubMed Web of Science ®Google Scholar
• Kanaani J, Lissin D, Kash SF, Baekkeskov S. The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophobic membrane-anchored isoform, GAD65. J Biol Chem 1999; 274:37200 - 9; http://dx.doi.org/10.1074/jbc.274.52.37200; PMID: 10601283
   PubMed Web of Science ®Google Scholar
• Pleau JM, Fernandez-Saravia F, Esling A, Homo-Delarche F, Dardenne M. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin Immunol Immunopathol 1995; 76:90 - 5; http://dx.doi.org/10.1006/clin.1995.1092; PMID: 7606872
   PubMedGoogle Scholar
• Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, et al. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001; 166:2122 - 32; PMID: 11160264
   PubMed Web of Science ®Google Scholar
• Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183:1561 - 7; http://dx.doi.org/10.1084/jem.183.4.1561; PMID: 8666914
   PubMed Web of Science ®Google Scholar
• Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47:894 - 9; http://dx.doi.org/10.2337/diabetes.47.6.894; PMID: 9604865
   PubMed Web of Science ®Google Scholar
• Agardh CD, Lynch KF, Palmér M, Link K, Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009; 52:1363 - 8; http://dx.doi.org/10.1007/s00125-009-1371-2; PMID: 19404608
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, Pihl M, Forsander G, et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011; 54:634 - 40; http://dx.doi.org/10.1007/s00125-010-1988-1; PMID: 21116604
   PubMed Web of Science ®Google Scholar
• Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev 2009; 25:316 - 20; http://dx.doi.org/10.1002/dmrr.942; PMID: 19267355
   PubMed Web of Science ®Google Scholar
• Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1991; 88:3088 - 91; http://dx.doi.org/10.1073/pnas.88.8.3088; PMID: 1707531
   PubMed Web of Science ®Google Scholar
• Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Könen-Waisman S, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997; 46:758 - 64; http://dx.doi.org/10.2337/diabetes.46.5.758; PMID: 9133541
   PubMed Web of Science ®Google Scholar
• Ablamunits V, Elias D, Reshef T, Cohen IR. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 1998; 11:73 - 81; http://dx.doi.org/10.1006/jaut.1997.0177; PMID: 9480725
   PubMed Web of Science ®Google Scholar
• Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999; 12:121 - 9; http://dx.doi.org/10.1006/jaut.1998.0262; PMID: 10047432
   PubMed Web of Science ®Google Scholar
• Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358:1749 - 53; http://dx.doi.org/10.1016/S0140-6736(01)06801-5; PMID: 11734230
   PubMed Web of Science ®Google Scholar
• Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007; 23:292 - 8; http://dx.doi.org/10.1002/dmrr.712; PMID: 17124720
   PubMed Web of Science ®Google Scholar
• Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4:989 - 97; http://dx.doi.org/10.1038/nri1502; PMID: 15573133
   PubMed Web of Science ®Google Scholar
• Culina S, Boitard C, Mallone R. Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?. Clin Dev Immunol 2011; 2011:286248; http://dx.doi.org/10.1155/2011/286248; PMID: 21647401
   PubMed Web of Science ®Google Scholar
• Achenbach P, Barker J, Bonifacio E, Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008; 8:87 - 93; http://dx.doi.org/10.1007/s11892-008-0017-y; PMID: 18445349
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122 - 6; http://dx.doi.org/10.1038/nature06939; PMID: 18496530
   PubMed Web of Science ®Google Scholar
• Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 2010; 18:307 - 16; http://dx.doi.org/10.1038/mt.2009.197; PMID: 19690518
   PubMed Web of Science ®Google Scholar
• Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116:1371 - 81; http://dx.doi.org/10.1172/JCI27191; PMID: 16628253
   PubMed Web of Science ®Google Scholar
• Baeke F, Van Belle TL, Takiishi T, Ding L, Korf H, Laureys J, et al. Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes. Diabetologia 2012; 55:2723 - 32; http://dx.doi.org/10.1007/s00125-012-2630-1; PMID: 22752077
   PubMed Web of Science ®Google Scholar
• Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61:145 - 54; http://dx.doi.org/10.2337/db11-1033; PMID: 22043003
   PubMed Web of Science ®Google Scholar
• Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002; 51:638 - 45; http://dx.doi.org/10.2337/diabetes.51.3.638; PMID: 11872661
   PubMed Web of Science ®Google Scholar
• Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al, Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012; 61:2340 - 8; http://dx.doi.org/10.2337/db12-0049; PMID: 22721971
   PubMed Web of Science ®Google Scholar
• Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007; 148:5136 - 44; http://dx.doi.org/10.1210/en.2007-0358; PMID: 17673522
   PubMed Web of Science ®Google Scholar
• Boettler T, von Herrath M. Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D. Int Immunopharmacol 2010; 10:1491 - 5; http://dx.doi.org/10.1016/j.intimp.2010.07.008; PMID: 20667487
   PubMed Web of Science ®Google Scholar
• Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012; 122:1717 - 25; http://dx.doi.org/10.1172/JCI60530; PMID: 22484814
   PubMed Web of Science ®Google Scholar